Mendelian disorders testing market research report: by test type (carrier testing, diagnostic testing, new-born screening), by disorder (cystic fibrosis, sickle cell anemia), by end-user (hospitals, ascs, specialized clinics) – Global forecast till 2027
ID: MRFR/LS/4053-HCR | February 2021 | Region: Global | 90 pages
Market Scenario:
Genetic testing involves the use of laboratory methods to study the genes inherited from mother or father. These tests may be used to identify increased risks of health problems, to diagnose the mutations in the genes, to choose treatments, or to assess responses to treatment.
Mendelian disorders also known as monogenic diseases arise due to the modifications in a single gene occurring in all cells of the body. Currently, it is estimated that over 10,000 of human diseases are known to be monogenic. These disorders are responsible for a heavy loss of life. The global prevalence of monogenic diseases at birth is approximately 10 in every 1000 infants.
The Mendelian disorders are caused by a single mutated gene which can be present on single or both chromosomes. Both females and males are equally affected by this disorder. Sickle cell anemia, Cystic fibrosis, Tay-Sachs disease, SCID, Gaucher's disease, Huntington's disease, neurofibromatosis, thalassemia, polycystic kidney disorder, and familial hypercholesterolemia are some of the common monogenic disorders. Nowadays, there are several tests performed to treat monogenic disorders such as diagnostic testing, carrier testing, predictive & pre-symptomatic testing, prenatal testing and new-born screening.
The carrier testing is a type of genetic testing that is used to determine a carrier person for monogenic disorders. Having said that, more and more genetic tests are being developed for a lot of other genetic disorders. Oncology segment has been the major focus area of the companies developing these tests as the large pool of population is affected by this fatal disease. The continuous rise in the prevalence of the genetic disorders has boosted the growth of the genetic testing market.
The global mendelian disorders testing market is expected to grow at a CAGR of approximately 6.5% during the forecast period 2017-2023.
Intended Audience
- Mendelian Disorders Test Kit Suppliers
- Mendelian Disorders Test Kit Manufacturers
- Research and Development (R&D) Companies
- Medical Research Laboratories
- Academic Medical Institutes and Universities
- Research Methodology
- Sources: Annual reports, Press release, White paper, and Company presentation
- Description: Mendelian disorders testing Market, Mendelian disorders testing, Mendelian disorders testing Market in Europe, Mendelian disorders testing Market in Asia Pacific, Mendelian disorders testing Market in the Middle East
Segmentation
The global Mendelian disorders testing market is segmented on the basis of test type, disorder type, and end-user.
On the basis of the test type, the global Mendelian disorders testing market is segmented into carrier testing, diagnostic testing, new-born screening, predictive & pre-symptomatic testing, prenatal testing, and others
On the basis of the disorder type, the global mendelian disorders testing market is segmented into cystic fibrosis, sickle cell anemia, severe combined immunodeficiency (SCID), Tay-Sachs disorder, polycystic kidney disorder, Gaucher's disease, Huntington's disease, neurofibromatosis, thalassemia, familial hypercholesterolemia, and others
On the basis of the end user, the global mendelian disorders testing market is segmented into hospitals, ambulatory surgical centers (ASCs), and specialized clinics.
Regional Analysis
The global Mendelian disorders testing market is segmented as the Americas, Europe, Asia Pacific and the Middle East and Africa.
The Americas is projected to hold the largest share of the global mendelian disorders testing market. The unique opportunity drives the Mendelian disorders testing the market, and the focused issues stress on the need for more research on monogenic disorder tests. In the United States, sickle cell anemia affects around 72,000 people, the majority of this population have their ancestors from Africa. All the factors above are anticipated to boost the market growth in the U.S. and ensure its dominance over the forecast period.
Europe is expected to capture the second lead in this market in the coming five years owing to substantial technological advancements. About 6,000 people are affected with hemophilia in the UK. Moreover, about 5400 people in the U.K with hemophilia A and about 1100 with hemophilia B.
The market in the Asia Pacific is expected to witness the fastest growth rate due to increasing prevalence of monogenic disorders throughout the globe, which will boost the growth of the monogenetic disorders testing market.
The Middle East and Africa are also expected to show healthy growth in the coming five years.
Key Players
The existing players are strengthening their foothold in the industry by introducing technologically advanced products. Regulatory bodies such as the US FDA and the European CE mark, although stringent, are approving equipment that fulfills all clinical data requirement and other safety criteria.
Some of key the players in the global mendelian disorders testing market are Celera Group (U.S.), Abbott Laboratories (U.S.), ELITechGroup (France), Quest Diagnostics (U.S.), AutoGenomics (U.S.), PerkinElmer Inc. (U.S.), Roche Diagnostics (Switzerland), Bio-Rad Laboratories, Inc. (U.S.), Applied Biosystems Inc. (U.S.), Transgenomic Inc. (U.S.), and others.
Frequently Asked Questions (FAQ) :
At what CAGR is the mendelian disorders testing market projected to grow during the forecast period?
The mendelian disorders testing market is projected to grow at a 6.5% CAGR between 2017-2023.
The Americas is projected to lead the mendelian disorders testing market.
Major end users of the mendelian disorders testing market include specialized clinics, ambulatory surgical centers, and hospitals.
Key players profiled in the mendelian disorders testing market include Transgenomic Inc. (US), Applied Biosystems Inc. (US), Bio-Rad Laboratories, Inc. (US), Roche Diagnostics (Switzerland), PerkinElmer Inc. (US), AutoGenomics (US), Quest Diagnostics (US), ELITechGroup (France), Abbott Laboratories (US), and Celera Group (US).
Strategies adopted by key players to strengthen their position in the mendelian disorders testing market include strategic alliances, mergers, partnerships, new product launches, and acquisitions.
TABLE OF CONTENT
Chapter 1. Report Prologue
Chapter 2. Market Introduction
2.1 Definition
2.2 Scope of the Study
2.2.1 Research Objective
2.2.2 Assumptions
2.2.3 Limitations
Chapter 3. Research Methodology
3.1 Introduction
3.2 Primary Research
3.3 Secondary research
3.4 Market Size Estimation
Chapter 4. Market Dynamics
4.1 Drivers
4.2 Restrains
4.3 Opportunities
4.4 Challenges
4.5 Macroeconomic Indicators
4.6 Technology Trends & Assessment
Chapter 5. Market Factor Analysis
5.1 Porter’s Five Forces Analysis
5.1.1 Bargaining Power of Suppliers
5.1.2 Bargaining Power of Buyers
5.1.3 Threat of New Entrants
5.1.4 Threat of Substitutes
5.1.5 Intensity of Rivalry
5.2 Value Chain Analysis
5.3 Investment Feasibility Analysis
5.4 Pricing Analysis
Chapter 6. Global Mendelian Disorders Testing Market, by Test Type
6.1 Introduction
6.2 Carrier Testing
6.2.1 Market Estimates & Forecast, 2020 – 2023
6.3 Diagnostic Testing
6.3.1 Market Estimates & Forecast, 2020 – 2023
6.4 New-born Screening
6.4.1 Market Estimates & Forecast, 2020 – 2023
6.5 Predictive & Pre-Symptomatic Testing
6.5.1 Market Estimates & Forecast, 2020 – 2023
6.6 Prenatal Testing
6.6.1 Market Estimates & Forecast, 2020 – 2023
Chapter 7. Global Mendelian Disorders Testing Market, by Disease Type
7.1 Introduction
7.2 Cystic fibrosis
7.2.1 Market Estimates & Forecast, 2020-2027
7.3 Sickle Cell Anemia
7.3.1 Market Estimates & Forecast, 2020-2027
7.4 Severe Combined Immunodeficiency (SCID)
7.4.1 Market Estimates & Forecast, 2020-2027
7.5 Tay-Sachs Disorder
7.5.1 Market Estimates & Forecast, 2020-2027
7.6 Polycystic Kidney Disorder
7.6.1 Market Estimates & Forecast, 2020-2027
7.7 Gaucher's Disease
7.7.1 Market Estimates & Forecast, 2020-2027
7.8 Huntington's Disease
7.8.1 Market Estimates & Forecast, 2020-2027
7.9 Neurofibromatosis
7.9.1 Market Estimates & Forecast, 2020-2027
7.10 Thalassemia
7.10.1 Market Estimates & Forecast, 2020-2027
7.11 Familial Hypercholesterolemia
7.11.1 Market Estimates & Forecast, 2020-2027
Chapter 8. Global Mendelian Disorders Testing Market, by End User
8.1 Introduction
8.2 Hospitals
8.2.1 Market Estimates & Forecast, 2020-2027
8.3 Ambulatory Surgical Centers
8.3.1 Market Estimates & Forecast, 2020-2027
8.4 Specialized Clinics
8.4.1 Market Estimates & Forecast, 2020-2027
Chapter. 9 Global Mendelian Disorders Testing Market, by Region
9.1 Introduction
9.2 Americas
9.2.1 North America
9.2.1.1 U.S.
9.2.1.1 Canada
9.2.2 South America
9.3 Europe
9.3.1 Western Europe
9.3.1.1 Germany
9.3.1.2 France
9.3.1.3 Italy
9.3.1.4 Spain
9.3.1.5 U.K
9.3.1.6 Rest of Western Europe
9.3.2 Eastern Europe
9.4 Asia Pacific
9.4.1 Japan
9.4.2 China
9.4.3 India
9.4.4 Australia
9.4.5 Republic of Korea
9.4.6 Rest of Asia Pacific
9.5 The Middle East & Africa
9.5.1 United Arab Emirates
9.5.2 Saudi Arabia
9.5.3 Rest of the Middle East & Africa
Chapter 10 Company Landscape
10.1 Introduction
10.2 Market Share Analysis
10.3 Key Development & Strategies
10.3.1 Key Developments
Chapter 11 Company Profiles
11.1 Celera Group
11.1.1 Company Overview
11.1.2 Disease Type Overview
11.1.3 Financials
11.1.4 SWOT Analysis
11.2 Abbott Laboratories
11.2.1 Company Overview
11.2.2 Disease Type Overview
11.2.3 Financial Overview
11.2.4 Key Developments
11.2.5 SWOT Analysis
11.3 ELITechGroup
11.3.1 Company Overview
11.3.2 Disease Type Overview
11.3.3 Financial Overview
11.3.4 Key Development
11.3.5 SWOT Analysis
11.4 Quest Diagnostics
11.4.1 Company Overview
11.4.2 Treatment/Business Segment Overview
11.4.3 Financial Overview
11.4.4 Key Development
11.4.5 SWOT Analysis
11.5 AutoGenomics
11.5.1 Company Overview
11.5.2 Disease Type Overview
11.5.3 Financial overview
11.5.4 Key Developments
11.6 PerkinElmer Inc.
11.6.1 Company Overview
11.6.2 Disease Type Overview
11.6.3 Financial Overview
11.6.4 Key Developments
11.7 Roche Diagnostics
11.7.1 Overview
11.7.2 Disease Type Overview
11.7.3 Financials
11.7.4 Key Developments
11.7.5 SWOT Analysis
11.8 Bio-Rad Laboratories, Inc.
11.8.1 Company Overview
11.8.2 Treatment/Business Segment Overview
11.8.3 Financial Overview
11.8.4 Key Development
11.8.5 SWOT Analysis
11.9 Applied Biosystems Inc.
11.9.1 Company Overview
11.9.2 Disease Type Overview
11.9.3 Financial overview
11.9.4 Key Developments
11.10 Transgenomic Inc.
11.10.1 Company Overview
11.10.2 Disease Type Overview
11.10.3 Financial overview
11.10.4 Key Developments
11.11 Others
Chapter 12 MRFR Conclusion
12.1 Key Findings
12.1.1 From CEO’s View Point
12.1.2 Unmet Needs of the Market
12.2 Key Companies to Watch
12.3 Prediction of Pharmaceutical industry
Chapter 13 Appendix
LIST OF TABLES
Table 1 Mendelian disorders testing Industry Synopsis, 2020-2027
Table 2 Mendelian Disorders Testing Market Estimates and Forecast, 2020-2027, (USD Million)
Table 3 Mendelian Disorders Testing Market by Region, 2020-2027, (USD Million)
Table 4 Mendelian Disorders Testing Market by Test Type, 2020-2027, (USD Million)
Table 5 Mendelian Disorders Testing Market by Treatment, 2020-2027, (USD Million)
Table 6 Mendelian Disorders Testing Market by End Users, 2020-2027, (USD Million)
Table 7 North America Mendelian Disorders Testing Market by Test Type, 2020-2027, (USD Million)
Table 8 North America Mendelian Disorders Testing Market by Treatment, 2020-2027, (USD Million)
Table 9 North America Mendelian Disorders Testing Market by End User, 2020-2027, (USD Million)
Table 10 US Mendelian Disorders Testing Market by Test Type, 2020-2027, (USD Million)
Table 11 US Mendelian Disorders Testing Market by Treatment, 2020-2027, (USD Million)
Table 12 US Mendelian Disorders Testing Market by End User, 2020-2027, (USD Million)
Table 13 Canada Mendelian Disorders Testing Market by Test Type, 2020-2027, (USD Million)
Table 14 Canada Mendelian Disorders Testing Market by Treatment, 2020-2027, (USD Million)
Table 15 Canada Mendelian Disorders Testing Market by End User, 2020-2027, (USD Million)
Table 16 South America Mendelian Disorders Testing Market by Test Type, 2020-2027, (USD Million)
Table 17 South America Mendelian Disorders Testing Market by Treatment, 2020-2027, (USD Million)
Table 18 South America Mendelian Disorders Testing Market by End User, 2020-2027, (USD Million)
Table 19 Europe Mendelian Disorders Testing Market by Test Type, 2020-2027, (USD Million)
Table 20 Europe Mendelian Disorders Testing Market by Treatment, 2020-2027, (USD Million)
Table 21 Europe Mendelian Disorders Testing Market by End User, 2020-2027, (USD Million)
Table 22 Western Europe Mendelian Disorders Testing Market by Test Type, 2020-2027, (USD Million)
Table 23 Western Europe Mendelian Disorders Testing Market by Treatment, 2020-2027, (USD Million)
Table 24 Western Europe Mendelian Disorders Testing Market by End User, 2020-2027, (USD Million)
Table 25 Eastern Europe Mendelian Disorders Testing Market by Test Type, 2020-2027, (USD Million)
Table 26 Eastern Europe Mendelian Disorders Testing Market by Treatment, 2020-2027, (USD Million)
Table 27 Eastern Europe Mendelian Disorders Testing Market by End User, 2020-2027, (USD Million)
Table 28 Asia Pacific Mendelian Disorders Testing Market by Test Type, 2020-2027, (USD Million)
Table 29 Asia Pacific Mendelian Disorders Testing Market by Treatment, 2020-2027, (USD Million)
Table 30 Asia Pacific Mendelian Disorders Testing Market by End User, 2020-2027, (USD Million)
Table 31 The Middle East & Africa Mendelian Disorders Testing Market by Test Type, 2020-2027, (USD Million)
Table 32 The Middle East & Africa Mendelian Disorders Testing Market by Treatment, 2020-2027, (USD Million)
Table 33 The Middle East & Africa Mendelian Disorders Testing Market by End User, 2020-2027, (USD Million)
LIST OF FIGURES
Figure 1 Research Process
Figure 2 Segmentation for Mendelian Disorders Testing Market
Figure 3 Segmentation Market Dynamics for Mendelian Disorders Testing Market
Figure 4 Global Mendelian Disorders Testing Market Share, by Test Type 2020
Figure 5 Global Mendelian Disorders Testing Market Share, by Disease Type2020
Figure 6 Global Mendelian Disorders Testing Market Share, by End Users, 2020
Figure 7 Global Mendelian Disorders Testing Market Share, by Region, 2020
Figure 8 North America Mendelian Disorders Testing Market Share, by Country, 2020
Figure 9 Europe Mendelian Disorders Testing Market Share, by Country, 2020
Figure 10 Asia Pacific Mendelian Disorders Testing Market Share, by Country, 2020
Figure 11 The Middle East & Africa Mendelian Disorders Testing Market Share, by Country, 2020
Figure 12 Global Mendelian Disorders Testing Market: Company Share Analysis, 2020 (%)
Figure 13 Celera Group: Key Financials
Figure 14 Celera Group: Segmental Revenue
Figure 15 Celera Group: Geographical Revenue
Figure 16 Abbott Laboratories: Key Financials
Figure 17 Abbott Laboratories: Segmental Revenue
Figure 18 Abbott Laboratories: Geographical Revenue
Figure 19 ELITechGroup: Key Financials
Figure 20 ELITechGroup: Segmental Revenue
Figure 22 ELITechGroup: Geographical Revenue
Figure 23 Quest Diagnostics: Key Financials
Figure 24 Quest Diagnostics: Segmental Revenue
Figure 25 Quest Diagnostics: Geographical Revenue
Figure 27 AutoGenomics: Key Financials
Figure 28 AutoGenomics: Segmental Revenue
Figure 29 AutoGenomics: Geographical Revenue
Figure 30 PerkinElmer Inc.: Key Financials
Figure 32 PerkinElmer Inc.: Segmental Revenue
Figure 33 PerkinElmer Inc.: Geographical Revenue
Figure 33 Tornier N.V.: Key Financials
Figure 34 Tornier N.V.: Segmental Revenue
Figure 35 Tornier N.V.: Geographical Revenue
Figure 36 Össur: Key Financials
Figure 37 Össur: Segmental Revenue
Figure 38 Össur: Geographical Revenue
Figure 39 Acumed, LLC: Key Financials
Figure 40 Acumed, LLC: Segmental Revenue
Figure 41 Acumed, LLC: Geographical Revenue
